Genotype and treatment initiation in clinically unclassified children with MEFV variants: a retrospective cohort study
This retrospective cohort study of 116 children with MEFV variants who initially did not meet Familial Mediterranean Fever criteria found that over half eventually required treatment initiation, with genotype (specifically M694V/E148Q) and baseline CRP levels identified as factors associated with starting therapy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine a child who comes to a doctor with a fever or a stomach ache that comes and goes, but the symptoms are vague and don't fit a clear pattern. The doctor runs a genetic test and finds a tiny variation in a specific gene called MEFV. This gene is linked to a condition known as Familial Mediterranean fever, a disease that causes recurring attacks of fever and pain. However, this child does not meet the strict medical rules for having the full-blown disease. They have the genetic marker, but not the classic story of the illness. This leaves doctors in a difficult position: should they start a lifelong medication to prevent future attacks, or should they wait and watch? Giving medicine to a child who might not need it carries its own burdens, but waiting too long could allow a hidden inflammation to cause serious damage later.
A team of researchers in Turkey set out to solve this uncertainty by looking back at the records of 116 children who found themselves in exactly this situation. These children, all under the age of eighteen, had been tested and found to carry at least one version of the MEFV gene, yet they did not qualify for a diagnosis of Familial Mediterranean fever when they were first seen. The doctors had not started them on treatment immediately. Instead, the researchers followed these children over time, tracking their health and noting when, if ever, a doctor decided to start them on a common medication called colchicine, which is used to calm the inflammation associated with this condition.
The study revealed that the decision to treat was not rare. About half of the children who started out without a clear diagnosis eventually began taking the medication. Most of these children started treatment within the first year of being watched. This suggests that for many of these children, the signs of the disease were simply too quiet to hear at the very first visit, but they became clearer as time went on. The researchers found that the children who eventually needed treatment were not easily spotted at the beginning by looking at their family history or by checking standard blood tests for inflammation. While the children who later got treatment had slightly higher levels of a specific protein called CRP in their blood, the difference was small, and other common markers did not help distinguish them from those who remained healthy without medicine.
The genetic makeup of the children offered some clues, though the picture was not entirely simple. The researchers looked at different types of gene variations. They found that children who carried two different variations were more likely to need treatment than those with just one. One specific combination of two variations, known as M694V and E148Q, was so strongly linked to the need for treatment that every single child in the study with this pair eventually started the medication. On the other hand, children who carried only one specific variation, E148Q, were much less likely to need treatment, with only a small fraction starting the drug. However, even among the children with just a single variation, half of them eventually required treatment, challenging the old idea that having only one gene variation means a child is safe from the disease.
The study concludes that a single visit is not enough to decide the fate of these children. Because so many of them developed symptoms or signs of inflammation later on, the researchers argue that these children need a structured plan for long-term observation rather than being sent home after one check-up. The decision to treat should not rely solely on family history or a snapshot of blood work, but rather on watching how the child's health evolves over time. While the study was limited by its size and the fact that it looked back at past records rather than planning the future, the findings provide a clear guide for doctors facing this common dilemma: keep watching, because for many of these children, the story of their illness is still being written.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.